Canadian Authorities Say Janssen Did Not Choke Competition For Infliximab – But Will Keep Spotlight On Originator Abuse Of Power
Executive Summary
In contrast to a US court, the competition authority in Canada has not found evidence that Janssen abused its power in the infliximab market and unlawfully stymied competition from Pfizer’s and Merck’s biosimilars. However, given the relative immaturity of the Canadian biosimilars market, the Competition Bureau said it would continue to watch closely as the market develops.